-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Compass Therapeutics, Maintains $30 Price Target

Benzinga·01/06/2026 14:39:57
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $30 price target.